Medix said the acquisition adds to its portfolio of raw materials used for in vitro diagnostics development and improves its ability to support immunoassay developers.

The partners plan to expand testing for early detection of childhood leukemias and lymphomas, bolster local testing capacity, and conduct a research study.

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.

The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.